About Incyte (NASDAQ:INCY)
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Debt
Debt-to-Equity Ratio0.01%
Current Ratio4.01%
Quick Ratio3.99%
Price-To-Earnings
Trailing P/E Ratio97.48
Forward P/E Ratio-389.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.54 billion
Price / Sales8.60
Cash Flow$0.7922 per share
Price / Cash78.70
Book Value$7.73 per share
Price / Book8.07
Profitability
EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-20.38%
Return on Equity-11.85%
Return on Assets-8.05%
Miscellaneous
Employees1,208
Outstanding Shares211,800,000
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) posted its earnings results on Thursday, February, 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.52) by $0.54. The biopharmaceutical company had revenue of $444.20 million for the quarter, compared to analyst estimates of $435.23 million. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. Incyte's revenue was up 36.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 EPS. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
22 brokerages have issued 1 year price targets for Incyte's stock. Their forecasts range from $65.00 to $174.00. On average, they anticipate Incyte's stock price to reach $117.55 in the next twelve months. View Analyst Ratings for Incyte.
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. According to Zacks Investment Research, "Incyte's Jakafi performance was strong in 2017 driven by patient demand. The sales guidance for 2018 was also impressive. Jakafi sales are expected to get a boost from the updated labels. Incyte expects Jakafi revenues in the range of $1.35-$1.4 billion in 2018, more than 20% growth over 2017. Meanwhile, the NDA for Olumiant was resubmitted and a potential approval will further boost the top line. Incyte’s pipeline is highly encouraging with promising immune therapies including epacadostat.. However, Incyte’s dependence on only Jakafi for growth is concerning. In addition, the recent failure of epacadostat study for the melanoma study with Keytruda was a big disappointment. Shares of the company have underperformed the industry in the last six months. Loss Estimates have narrowed ahead of the Q1 earnings results. The company has a mixed record of earnings surprises in recent quarters." (4/19/2018)
- 2. Cowen Inc analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), ICON (ICLR), Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Viralytics (VRACY).
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
- Mr. David W. Gryska, Exec. VP & CFO (Age 63)
- Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)
Has Incyte been receiving favorable news coverage?
News coverage about INCY stock has been trending positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Incyte earned a news impact score of 0.25 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $62.44.
How big of a company is Incyte?
Incyte has a market capitalization of $14.49 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Incyte (NASDAQ:INCY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
22 Wall Street analysts have issued ratings and price targets for Incyte in the last 12 months. Their average twelve-month price target is $117.55, suggesting that the stock has a possible upside of 88.53%. The high price target for INCY is $174.00 and the low price target for INCY is $65.00. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.68 | 2.71 | 2.74 | 2.78 |
| Ratings Breakdown: | 0 Sell Rating(s)
7 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $117.55 | $142.3684 | $142.8571 | $144.4762 |
| Price Target Upside: | 88.53% upside | 64.45% upside | 53.35% upside | 26.13% upside |
Incyte (NASDAQ:INCY) Consensus Price Target History
Incyte (NASDAQ:INCY) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Incyte (NASDAQ:INCY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Incyte (NASDAQ INCY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.20%
Institutional Ownership Percentage: 93.58%
Incyte (NASDAQ INCY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/21/2018 | David W Gryska | Insider | Sell | 1,952 | $85.56 | $167,013.12 | 12,922 |  |
| 2/21/2018 | Reid M Huber | EVP | Sell | 1,958 | $85.55 | $167,506.90 | | |
| 1/5/2018 | David W Gryska | Insider | Sell | 6,760 | $98.87 | $668,361.20 | 20,752 | |
| 1/2/2018 | Vijay K Iyengar | EVP | Sell | 5,000 | $97.26 | $486,300.00 | | |
| 12/1/2017 | Reid M Huber | EVP | Sell | 696 | $98.01 | $68,214.96 | | |
| 11/16/2017 | Paul A Friedman | Director | Sell | 28,507 | $105.24 | $3,000,076.68 | | |
| 11/2/2017 | David W Gryska | Insider | Sell | 3,915 | $105.63 | $413,541.45 | | |
| 9/18/2017 | Herve Hoppenot | President | Sell | 70,502 | $119.45 | $8,421,463.90 | | |
| 9/14/2017 | Barry P Flannelly | EVP | Sell | 714 | $124.25 | $88,714.50 | 15,496 | |
| 9/8/2017 | Bros. Advisors Lp Baker | Director | Buy | 100,000 | $132.00 | $13,200,000.00 | | |
| 9/5/2017 | Paul Trower | Insider | Sell | 3,000 | $138.41 | $415,230.00 | 14,853 | |
| 9/1/2017 | Eric H Siegel | EVP | Sell | 1,820 | $137.40 | $250,068.00 | 23,553 | |
| 8/31/2017 | Paula J Swain | EVP | Sell | 20,000 | $140.00 | $2,800,000.00 | 55,067 | |
| 8/29/2017 | Steven H Stein | EVP | Sell | 2,111 | $125.00 | $263,875.00 | 18,687 | |
| 8/4/2017 | Paul Trower | Insider | Sell | 3,000 | $125.25 | $375,750.00 | 11,853 | |
| 8/1/2017 | Eric H Siegel | EVP | Sell | 1,820 | $132.92 | $241,914.40 | 23,553 | |
| 7/20/2017 | Steven H Stein | EVP | Sell | 6,485 | $131.09 | $850,118.65 | 19,356 | |
| 7/5/2017 | Paul Trower | Insider | Sell | 3,000 | $126.18 | $378,540.00 | 12,148 | |
| 7/3/2017 | Eric H Siegel | EVP | Sell | 1,820 | $126.20 | $229,684.00 | 20,036 | |
| 6/30/2017 | David W Gryska | Insider | Sell | 599 | $129.74 | $77,714.26 | 19,614 | |
| 6/20/2017 | Steven H Stein | EVP | Sell | 9,883 | $125.00 | $1,235,375.00 | 18,518 | |
| 6/12/2017 | David W Gryska | CFO | Sell | 16,756 | $116.60 | $1,953,749.60 | 35,771 | |
| 6/5/2017 | Paul Trower | Insider | Sell | 3,000 | $132.50 | $397,500.00 | 13,950 | |
| 6/1/2017 | Eric H Siegel | EVP | Sell | 1,820 | $130.00 | $236,600.00 | 18,744 | |
| 5/31/2017 | Jean Jacques Bienaime | Director | Buy | 500 | $131.80 | $65,900.00 | 4,677 | |
| 5/15/2017 | Jean Jacques Bienaime | Director | Buy | 500 | $115.00 | $57,500.00 | 4,177 | |
| 5/8/2017 | Reid M Huber | EVP | Sell | 8,577 | $119.21 | $1,022,464.17 | 44,614 | |
| 5/1/2017 | Eric H Siegel | EVP | Sell | 1,820 | $124.73 | $227,008.60 | 18,744 | |
| 4/28/2017 | Jean Jacques Bienaime | Director | Buy | 500 | $124.26 | $62,130.00 | 3,677 | |
| 4/13/2017 | Jean Jacques Bienaime | Director | Buy | 1,000 | $139.66 | $139,660.00 | 3,177 | |
| 4/10/2017 | David W Gryska | Insider | Sell | 41,528 | $138.00 | $5,730,864.00 | 20,754 | |
| 4/10/2017 | Eric H Siegel | EVP | Sell | 4,043 | $140.18 | $566,747.74 | 19,008 | |
| 4/7/2017 | Jean Jacques Bienaime | Director | Buy | 1,000 | $139.48 | $139,480.00 | 2,177 | |
| 4/7/2017 | Steven H Stein | EVP | Sell | 32,000 | $137.88 | $4,412,160.00 | 41,648 | |
| 3/17/2017 | Paul A Friedman | Director | Sell | 50,000 | $148.72 | $7,436,000.00 | 302,976 | |
| 1/9/2017 | Reid M. Huber | EVP | Sell | 11,739 | $113.55 | $1,332,963.45 | | |
| 11/9/2016 | Reid M. Huber | EVP | Sell | 2,715 | $109.95 | $298,514.25 | | |
| 10/20/2016 | Paula J Swain | EVP | Sell | 10,000 | $90.00 | $900,000.00 | 39,248 | |
| 10/7/2016 | Barry P Flannelly | EVP | Sell | 24,204 | $97.00 | $2,347,788.00 | 13,595 | |
| 9/23/2016 | Paula J Swain | EVP | Sell | 20,000 | $90.00 | $1,800,000.00 | 49,248 | |
| 8/2/2016 | Reid M. Huber | EVP | Sell | 10,000 | $87.96 | $879,600.00 | | |
| 7/29/2016 | Paula J Swain | EVP | Sell | 60,000 | $90.00 | $5,400,000.00 | 89,248 | |
| 3/17/2016 | Julian Baker | Director | Buy | 800,000 | $63.98 | $51,184,000.00 | 58,632 | |
| 2/25/2016 | Julian Baker | Director | Buy | 64,290 | $70.79 | $4,551,089.10 | | |
| 2/16/2016 | Julian Baker | Director | Buy | 887,165 | $69.87 | $61,986,218.55 | | |
| 2/12/2016 | Julian Baker | Director | Buy | 2,251,427 | $63.53 | $143,033,157.31 | | |
| 1/15/2016 | Paula J. Swain | EVP | Sell | 13,531 | $76.96 | $1,041,345.76 | 23,693 | |
| 1/6/2016 | Richard S. Levy | EVP | Sell | 3,937 | $101.86 | $401,022.82 | 16,926 | |
| 12/7/2015 | Richard S. Levy | EVP | Sell | 3,937 | $106.18 | $418,030.66 | 16,926 | |
| 11/18/2015 | Paul A. Friedman | Director | Sell | 225,000 | $113.83 | $25,611,750.00 | 297,518 | |
| 11/10/2015 | Eric H. Siegel | EVP | Sell | 2,222 | $104.86 | $232,998.92 | 3,710 | |
| 11/6/2015 | Richard S. Levy | EVP | Sell | 3,936 | $116.51 | $458,583.36 | 16,926 | |
| 11/3/2015 | Yao Wenqing | EVP | Sell | 5,786 | $124.78 | $721,977.08 | 21,371 | |
| 10/13/2015 | Eric H. Siegel | EVP | Sell | 2,222 | $101.49 | $225,510.78 | 3,355 | |
| 10/6/2015 | Richard S. Levy | EVP | Sell | 3,937 | $122.29 | $481,455.73 | 16,926 | |
| 9/21/2015 | Reid M. Huber | EVP | Sell | 10,000 | $124.29 | $1,242,900.00 | 62,865 | |
| 9/16/2015 | Eric H. Siegel | EVP | Sell | 2,222 | $130.69 | $290,393.18 | 3,355 | |
| 9/11/2015 | Richard S Levy | EVP | Sell | 4,301 | $130.00 | $559,130.00 | 16,926 | |
| 9/8/2015 | Richard S. Levy | EVP | Sell | 3,937 | $118.90 | $468,109.30 | 21,227 | |
| 8/13/2015 | Eric H Siegel | EVP | Sell | 2,222 | $107.69 | $239,287.18 | | |
| 7/15/2015 | Richard S Levy | EVP | Sell | 70,217 | $120.00 | $8,426,040.00 | | |
| 7/14/2015 | Eric H Siegel | EVP | Sell | 2,222 | $113.61 | $252,441.42 | | |
| 7/6/2015 | Richard S Levy | EVP | Sell | 3,937 | $107.00 | $421,259.00 | | |
| 6/23/2015 | James M Daly | EVP | Sell | 11,691 | $108.24 | $1,265,433.84 | | |
| 6/19/2015 | Richard S Levy | EVP | Sell | 20,000 | $108.13 | $2,162,600.00 | | |
| 6/12/2015 | Eric H Siegel | EVP | Sell | 2,223 | $105.31 | $234,104.13 | | |
| 6/8/2015 | Richard S Levy | EVP | Sell | 3,937 | $107.58 | $423,542.46 | | |
| 5/27/2015 | Paul A Friedman | Director | Sell | 196,751 | $107.23 | $21,097,609.73 | | |
| 5/22/2015 | Paul A Friedman | Director | Sell | 102,243 | $108.22 | $11,064,737.46 | | |
| 5/14/2015 | Eric H Siegel | EVP | Sell | 2,222 | $104.99 | $233,287.78 | | |
| 4/23/2015 | James M Daly | EVP | Sell | 36,941 | $107.67 | $3,977,437.47 | | |
| 4/17/2015 | Yao Wenqing | EVP | Sell | 7,150 | $102.04 | $729,586.00 | | |
| 4/14/2015 | Eric H Siegel | EVP | Sell | 2,222 | $98.72 | $219,355.84 | | |
| 4/13/2015 | Yao Wenqing | EVP | Sell | 23,000 | $95.18 | $2,189,140.00 | | |
| 4/7/2015 | Yao Wenqing | EVP | Sell | 20,031 | $90.13 | $1,805,394.03 | | |
| 3/30/2015 | Laurent Chardonnet | VP | Sell | 113,776 | $93.64 | $10,653,984.64 | | |
| 3/30/2015 | Reid M Huber | EVP | Sell | 34,263 | $93.66 | $3,209,072.58 | | |
| 3/12/2015 | Barry A Ariko | Director | Sell | 80,000 | $89.27 | $7,141,600.00 | | |
| 3/12/2015 | Eric H Siegel | EVP | Sell | 2,222 | $89.72 | $199,357.84 | | |
| 2/25/2015 | Eric H Siegel | EVP | Sell | 13,333 | $85.00 | $1,133,305.00 | | |
| 2/24/2015 | James M Daly | EVP | Sell | 11,112 | $82.19 | $913,295.28 | | |
| 2/17/2015 | Paula J Swain | EVP | Sell | 17,500 | $76.90 | $1,345,750.00 | | |
| 1/26/2015 | Eric H Siegel | EVP | Sell | 13,542 | $79.85 | $1,081,328.70 | | |
| 1/23/2015 | James M Daly | EVP | Sell | 11,109 | $77.68 | $862,947.12 | | |
| 1/20/2015 | Paula J Swain | EVP | Sell | 17,500 | $74.17 | $1,297,975.00 | | |
| 1/16/2015 | Richard S Levy | EVP | Sell | 12,000 | $73.07 | $876,840.00 | | |
| 1/8/2015 | Eric H Siegel | EVP | Sell | 15,626 | $75.00 | $1,171,950.00 | | |
| 1/6/2015 | Richard S Levy | EVP | Sell | 25,000 | $71.84 | $1,796,000.00 | | |
| 1/5/2015 | Paula J Swain | EVP | Sell | 17,500 | $73.90 | $1,293,250.00 | | |
| 12/23/2014 | James M Daly | EVP | Sell | 11,113 | $74.43 | $827,140.59 | | |
| 12/2/2014 | Schutter Richard U De | Chairman | Sell | 50,000 | $74.89 | $3,744,500.00 | | |
| 11/6/2014 | Paul A Friedman | Director | Sell | 185,653 | $67.87 | $12,600,269.11 | | |
| 10/23/2014 | James M Daly | EVP | Sell | 11,111 | $53.49 | $594,327.39 | | |
| 9/23/2014 | James M Daly | EVP | Sell | 11,111 | $47.65 | $529,439.15 | | |
| 9/16/2014 | Richard S Levy | EVP | Sell | 8,000 | $47.58 | $380,640.00 | | |
| 8/18/2014 | Richard S Levy | EVP | Sell | 8,000 | $51.97 | $415,760.00 | | |
| 7/23/2014 | James M Daly | EVP | Sell | 11,111 | $48.54 | $539,327.94 | | |
| 7/16/2014 | Richard S Levy | EVP | Sell | 8,000 | $48.15 | $385,200.00 | | |
| 6/23/2014 | James M Daly | EVP | Sell | 11,111 | $56.03 | $622,549.33 | | |
| 6/16/2014 | Richard S Levy | EVP | Sell | 8,000 | $53.88 | $431,040.00 | | |
| 6/5/2014 | David C Hastings | CFO | Sell | 200,000 | $52.73 | $10,546,000.00 | | |
| 5/23/2014 | James M Daly | EVP | Sell | 11,111 | $48.48 | $538,661.28 | | |
| 5/16/2014 | Richard Levy | EVP | Sell | 8,000 | $50.68 | $405,440.00 | 4,301 | |
| 5/2/2014 | Laurent Chardonnet | VP | Sell | 34,000 | $51.55 | $1,752,700.00 | 3,811 | |
| 4/23/2014 | James Daly | EVP | Sell | 30,555 | $47.71 | $1,457,779.05 | | |
| 2/20/2014 | Paul Friedman | Director | Sell | 33,354 | $63.51 | $2,118,312.54 | 417,518 | |
| 2/19/2014 | Paul Friedman | Director | Sell | 771,182 | $65.65 | $50,628,098.30 | 417,518 | |
| 2/19/2014 | Schutter Richard De | Chairman | Sell | 50,000 | $65.53 | $3,276,500.00 | 155,000 | |
| 2/18/2014 | David Hastings | CFO | Sell | 275,000 | $65.86 | $18,111,500.00 | 8,500 | |
| 9/10/2013 | Paul A Friedman | CEO | Sell | 376,789 | $37.32 | $14,061,765.48 | | |
| 9/9/2013 | Laurent Chardonnet | VP | Sell | 44,834 | $37.31 | $1,672,756.54 | | |
| 9/6/2013 | David C Hastings | CFO | Sell | 100,000 | $35.16 | $3,516,000.00 | | |
| 9/6/2013 | Richard S Levy | EVP | Sell | 25,000 | $35.28 | $882,000.00 | | |
| 9/5/2013 | Paula J Swain | EVP | Sell | 94,444 | $35.06 | $3,311,206.64 | | |
| 8/19/2013 | Roy Whitfield | Director | Sell | 50,000 | $26.70 | $1,335,000.00 | 671,082 | |
| 5/17/2013 | Roy A Whitfield | Director | Sell | 40,000 | $23.08 | $923,200.00 | | |
| 5/13/2013 | Richard S Levy | EVP | Sell | 55,699 | $22.30 | $1,242,087.70 | | |
(Data available from 1/1/2013 forward)
Incyte (NASDAQ INCY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Incyte's (INCY) "Buy" Rating Reaffirmed at Raymond James
www.americanbankingnews.com - April 24 at 9:30 AM |
| Incyte (INCY) PT Lowered to $88.00
www.americanbankingnews.com - April 24 at 9:12 AM |
 | FDA Votes 10-5 to Back Incyte (INCY) and Lilly's (LLY) Baricitinib 2 mg, Votes 5-10 Against 4 mg
www.streetinsider.com - April 24 at 8:23 AM |
 | BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration
www.reuters.com - April 24 at 8:23 AM |
| Incyte (INCY) PT Raised to $77 at RBC Capital; 'Base Case'
www.streetinsider.com - April 24 at 8:23 AM |
| FDA panel against higher dose of Lilly-Incyte arthritis drug
www.reuters.com - April 24 at 8:23 AM |
 | Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced ...
globenewswire.com - April 24 at 8:23 AM |
 | Eli Lilly, Incyte shares drop after mixed FDA drug recommendation
finance.yahoo.com - April 24 at 8:23 AM |
| Incyte (INCY) Given a $65.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 24 at 8:20 AM |
| Incyte (INCY) to Release Earnings on Tuesday
www.americanbankingnews.com - April 24 at 6:13 AM |
| Incyte (INCY), Eli Lilly (LLY) Panel Going More Favorably Than Previously Suggested - RBC
www.streetinsider.com - April 23 at 5:09 PM |
| Incyte (INCY), Lilly (LLY) Low Dose Baricitinib Wins FDA Panel Vote on Safety; High Does Fails to Win Panel Vote on ...
www.streetinsider.com - April 23 at 5:09 PM |
| FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug
finance.yahoo.com - April 23 at 5:09 PM |
| Head-To-Head Contrast: Incyte (INCY) versus Intrexon (XON)
www.americanbankingnews.com - April 23 at 9:14 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)
finance.yahoo.com - April 20 at 5:18 PM |
| Incyte (INCY) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 20 at 12:13 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY
finance.yahoo.com - April 19 at 5:34 PM |
| Incyte (INCY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:49 PM |
| ValuEngine Lowers Incyte (INCY) to Strong Sell
www.americanbankingnews.com - April 18 at 11:22 PM |
| Incyte (INCY) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 3:31 PM |
| Incyte (INCY) Given a $78.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 18 at 8:47 AM |
 | What's Next for Incyte?
www.fool.com - April 17 at 8:39 AM |
 | Days After a Shocking Cancer Failure, Incyte Goes Back to Work
www.bloomberg.com - April 16 at 5:17 PM |
| What Incyte's Phase 3 Fail Means for Immuno-Oncology
finance.yahoo.com - April 16 at 5:17 PM |
| Incyte (INCY) and PRA Health Sciences (PRAH) Critical Survey
www.americanbankingnews.com - April 15 at 11:15 AM |
| What Happened With Incyte's IDO Inhibitor Flop
www.fool.com - April 14 at 8:28 AM |
| What Happened With Incyte's IDO Inhibitor Flop
finance.yahoo.com - April 14 at 8:28 AM |
 | Industrials, airlines, energy & biotech in the blitz
www.cnbc.com - April 13 at 8:29 AM |
| Incyte to Report First Quarter Financial Results
finance.yahoo.com - April 13 at 8:29 AM |
| $387.35 Million in Sales Expected for Incyte Co. (INCY) This Quarter
www.americanbankingnews.com - April 13 at 3:51 AM |
| Why GoPro, Incyte, and Wynn Resorts Jumped Today
finance.yahoo.com - April 12 at 5:33 PM |
| Contrasting Incyte (INCY) and Syneos Health (SYNH)
www.americanbankingnews.com - April 12 at 3:46 PM |
| Incyte (INCY) Stock Rating Upgraded by UBS
www.americanbankingnews.com - April 12 at 10:19 AM |
| -$0.12 EPS Expected for Incyte Co. (INCY) This Quarter
www.americanbankingnews.com - April 11 at 11:18 AM |
| Is Beaten-Down Incyte Corporation Stock a Buy Now?
finance.yahoo.com - April 11 at 8:36 AM |
| Oppenheimer Weighs in on Incyte Co.'s Q1 2018 Earnings (INCY)
www.americanbankingnews.com - April 11 at 8:05 AM |
 | Acadia, Incyte Show the Way to Monday's 52-Week Low Club
247wallst.com - April 10 at 8:35 AM |
| Investors Buy Large Volume of Put Options on Incyte (INCY)
www.americanbankingnews.com - April 10 at 7:44 AM |
| Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
finance.yahoo.com - April 9 at 5:16 PM |
| Incyte Cancer Drug Flop Is Costly and Likely to Be Duplicated
finance.yahoo.com - April 9 at 5:16 PM |
| Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial
finance.yahoo.com - April 9 at 5:16 PM |
| Incyte (INCY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase
www.americanbankingnews.com - April 9 at 11:02 AM |
| Credit Suisse Group Trims Incyte (INCY) Target Price to $76.00
www.americanbankingnews.com - April 9 at 9:56 AM |
| Incyte (INCY) Price Target Lowered to $76.00 at Morgan Stanley
www.americanbankingnews.com - April 9 at 9:55 AM |
| Incyte (INCY) Downgraded by Gabelli
www.americanbankingnews.com - April 9 at 8:50 AM |
 | Incyte Falls After Phase 3 Flop, But The Sky Isn't Falling
seekingalpha.com - April 9 at 8:26 AM |
| [$$] Biotech Gets a Reality Check
finance.yahoo.com - April 9 at 8:26 AM |
| Today’s Research Reports on Stocks to Watch: Incyte and Merck
finance.yahoo.com - April 9 at 8:26 AM |
| Incyte (INCY) Price Target Lowered to $102.00 at Nomura
www.americanbankingnews.com - April 9 at 8:25 AM |
| Incyte (INCY) PT Set at $65.00 by Oppenheimer
www.americanbankingnews.com - April 9 at 7:54 AM |
Incyte (NASDAQ:INCY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Incyte (NASDAQ:INCY) Income Statement, Balance Sheet and Cash Flow Statement
Incyte (NASDAQ INCY) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
